Aging cells exhibit two non‑exclusive phenomena: they traverse canonical differentiation trajectories more slowly and they can acquire novel pathological states that are absent in young tissues. Here we propose that the slowdown itself creates a temporal window during which the chromatin landscape becomes permissive to ectopic remodeling factors, thereby diverting cells from the canonical path into aberrant states. In young cells, rapid progression through activation or differentiation trajectories limits the dwell time of transcription factors at enhancers, restricting access to nucleosome‑modifying complexes. When pseudotime velocity declines—as observed in aged muscle stem cells [1]—the prolonged occupancy of pioneer factors such as EGR1 (downregulated in brain aging via reduced chromatin accessibility [3]) or Cep290‑associated centrosomal regulators [4] allows secondary chromatin modifiers, including histone acetyltransferases and DNA methyltransferases, to act on loci that are normally insulated. This epigenetic drift generates de‑novo enhancer usage and activates stress‑responsive or senescence‑associated programs, producing the novel cell states identified in cross‑tissue analyses [5,6]. Importantly, the model predicts that restoring trajectory velocity—for example by overexpressing cell‑cycle regulators that accelerate G1‑S transition—should suppress ectopic chromatin remodeling and reduce the emergence of pathological states, even in the presence of age‑related damage. Conversely, artificially slowing pseudotime in young cells (e.g., via CDK inhibition) should recapitulate the epigenetic drift and induce analogous novel states, providing a falsifiable test.

To test this, we propose a three‑pronged approach: (1) Perform joint RNA‑velocity and ATAC‑velocity measurements on young and old muscle stem cells to quantify dwell time of EGR1‑bound enhancers; (2) Use CRISPR‑based activation of a synthetic transcriptional accelerator (e.g., a destabilized cyclin D1) to increase pseudotime velocity in aged cells and assay for loss of novel ATAC peaks and reduced expression of senescence markers; (3) Apply reversible CDK4/6 inhibition to young cells to slow pseudotime and monitor gain of the same ATAC peaks and transcriptional signatures seen in aged novel states. A failure to observe these reciprocal changes would falsify the hypothesis, whereas consistent bidirectional shifts would support the kinetic checkpoint model of aging‑driven pathological state acquisition.